HCT/Ps were not processed in a way that does not cause contamination or cross contamination during processing and that does not increase the risk of introduction, transmission, or spread of communicable disease.
Inspection Record
Nelson Laboratories, LLC — FDA 483 Findings
Inspectors Emily B Camire · Laurissa S FlowersThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Each lot of components was not appropriately identified as to its status in terms of being quarantined, approved or rejected.
In-process inspections, tests, or other verification activities and approvals were not documented.
The quality program has not ensured the proper training and education of personnel involved in core GTP activities.
Deviations from written production and process control procedures are not justified.
Specified requirements for in-process controls were not met.
The quality program has not established and maintained appropriate monitoring systems.
Records were not detailed as necessary to provide a complete history of work performed.
Environmental conditions existed in which contamination or cross contamination of HCT/Ps or equipment could occur, and environmental conditions were not adequately controlled.
Procedures were not designed to prevent circumstances that increase the risk of communicable disease introduction, transmission and spread through the use of HCT/Ps.
Laboratory records are deficient in that they do not include a complete record of all data obtained during testing.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- Omrix Biopharmaceuticals Ltd.2020-03-05 · US FDASimilar to finding 11 Laboratory records are deficient in that they do not include a complete record of all data obtained during testing.
- Musculoskeletal Transplant Foundation2015-07-23 · US FDASimilar to finding 7 The quality program has not established and maintained appropriate monitoring systems.
- Neeyaan LLC2026-01-27 · US FDASimilar to finding 11 Laboratory records are deficient in that they do not include a complete record of all data obtained during testing.
- Aurobindo Pharma Limited, Unit VII2026-02-10 · US FDASimilar to finding 11 Laboratory records are deficient in that they do not include a complete record ofall data obtained during testing.
- Octapharma AB2023-09-19 · US FDASimilar to finding 5 Deviations from written production and process control procedures are not recorded and justified.
A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.